key: cord-0985528-mcglrf3b
authors: Samrat, Subodh Kumar; Tharappel, Anil M.; Li, Zhong; Li, Hongmin
title: Prospect of SARS-CoV-2 spike protein: Potential role in vaccine and therapeutic development
date: 2020-08-23
journal: Virus Res
DOI: 10.1016/j.virusres.2020.198141
sha: 79cdafe81622d86941277bdf6af4fc7b8f72f3c5
doc_id: 985528
cord_uid: mcglrf3b

The recent outbreak of the betacoronavirus SARS-CoV-2 has become a significant concern to public health care worldwide. As of August 19, 2020, more than 22,140,472 people are infected, and over 781,135 people have died due to this deadly virus. In the USA alone, over 5,482,602 people are currently infected, and more than 171,823 people have died. SARS-CoV-2 has shown a higher infectivity rate and a more extended incubation period as compared to previous coronaviruses. SARS-CoV-2 binds much more strongly than SARS-CoV to the same host receptor, angiotensin-converting enzyme 2 (ACE2). Previously, several methods to develop a vaccine against SARS-CoV or MERS-CoV have been tried with limited success. Since SARS-CoV-2 uses the spike (S) protein for entry to the host cell, it is one of the most preferred targets for making vaccines or therapeutics against SARS-CoV-2. In this review, we have summarised the characteristics of the S protein, as well as the different approaches being used for the development of vaccines and/or therapeutics based on the S protein.

In December 2019, Wuhan in the Hubei province of China became the center of an outbreak of pneumonia of unknown cause, which raised intense attention not only within China but internationally. Later, it was confirmed that the causative agent for this pneumonia-like disease is a coronavirus (CoV) belonging to the family Coronaviridae (Jiang et al., 2020a; Zhou et al., 2020) . On February 11, 2020, the World Health Organization named the virus SARS-CoV-2 and renamed the syndrome from 2019-nCoV to COVID-19, short for coronavirus disease 2019 ("WHO. Novel Coronavirus(2019-nCoV) Situation Report -22. February 11, 2020 . https://www.who.int/docs/defaultsource/coronaviruse/situation-reports/20200211-sitrep-22-ncov.pdf. Accessed May27, 2020.," n.d.) . COVID-19, a respiratory disease, has led to more than 22,140,472 confirmed cases and over 781,135 deaths globally as of August 19, 2020. In the USA alone, over 5,482,602 people are currently infected with SARS-CoV-2, which has caused more than 171,823 deaths ("Johns Hopkins University: https://coronavirus.jhu.edu/map.html. Accessed on August 19, 2020.," n.d.)

The first coronavirus pandemic of the 21st century occurred in November 2002, when an infectious agent caused outbreaks of atypical pneumonia in Guangdong Province, southern China, and Southeast Asia, North America, and Europe. By the end of February 2003, the virus had spread to neighboring regions and countries. The disease caused by the virus was named severe acute respiratory syndrome (SARS), for which a global alert was issued by WHO on March 13, 2003 (Lee et al., 2003 Tsang et al., 2003; Zhong et al., 2003) . SARS caused a global pandemic in [2002] [2003] , with approximately 10% (774/8098) case fatality rate (CFR) ( (Jiang et al., 2020a; Lee et al., 2003) . The SARS-causing coronavirus SARS-CoV has not circulated in humans since 2004. not develop any disease symptoms, but they can transmit the virus. One investigation in China suggested that the R0 of SARS-CoV-2 was as high as 4.7 to 6.6 before any infection control measures were applied (Sanche et al., 2020) , suggesting that SARS-CoV-2 is highly contagious and more infectious than previously estimated. These findings are also supported by the fact that the SARS-CoV-2-RBD demonstrates 10-20 fold higher affinity to the human ACE2 receptor than SARS-CoV (Tai et al., 2020; Wrapp et al., 2020a) .

To date, there is no approved drug for treatment of COVID-19, but an experimental antiviral drug with a known safety profile is currently being used for treatment of COVID-19 patients. It has been shown that the nucleotide analog Remdesivir can inhibit SARS-CoV and MERS-CoV in tissue culture and nonhuman animal models (Martinez, 2020) . A clinical trial of Remdesivir is underway for treatment of Ebola virus infection. Recently clinical trials for Remdesivir have been started for SARS-CoV-2 as well ; George Sakoulas, 2020; C. J. Gordon et al., 2020) . Despite much research and effort, there is no vaccine available for SARS-CoV-2 or any other coronaviruses. The diversity of the S-protein also renders any vaccines and nAbs unlikely to be cross-protective between existing and emerging CoVs.

The role of the S protein in binding with host receptors makes it a perfect target for vaccine and antiviral therapeutic development. Previous studies on SARS-CoV and MESR-CoV have revealed that vaccines based on the S protein can induce antibodies to block virus binding and fusion or neutralize virus infection ( (Du et al., 2009a) . Since the S protein plays a role in both virus entry and viral RNA release into the cytoplasm, a vaccine against the S protein should induce antibodies to block viral entry ( Figure 1 ). Previous reports suggest that immunization of J o u r n a l P r e -p r o o f mice with a trimeric form of MERS-CoV S protein RBD domain elicits potent neutralizing antibodies against MERS CoV (Coleman et al., 2017; Du et al., 2013; Mou et al., 2013; Tai et al., 2016) ;. Other studies show that immunization of rabbits with an RBD-Fc fusion protein elicits robust antibody responses, and the antisera can completely block SARS-CoV infection at different serum dilution Coleman et al., 2014; Du et al., 2009b; He et al., 2004) . Another study showed that immunization of mice with the S1 subunit of MERS-CoV actively induces neutralizing antibody production. Using the same strategy, the S1 subunit of SARS-CoV-2 can also induce S1-specific IgG in mice. However, further studies are required to verify the potency of the antibodies (Kim et al., 2020) . Also, development of a vaccine targeting the S protein is always challenging, as a vaccine based on neutralizing antibodies may lead to antibody-dependent enhancement of secondary virus infection and vaccine-enhanced disease. o u r n a l P r e -p r o o f monomer. Its S1 subunit contains the N-terminal domain (NTD; 14-305 aa), receptor binding domain (RBD; 319-541 aa), and receptor binding motif (RBM; 437-508 aa). Its S2 subunit contains fusion peptide (FP; 788-806 aa), heptad repeat 1 (HR1;12-984 aa), heptad repeat 2 (HR2;1163-1213 aa), transmembrane domain (TM;1214-1237 aa), and cytoplasmic domain (CP; 1238 -1273 . The predicted glycosylation sites are indicated above the domain bars. B.

Overall structure of the SARS-CoV-2 RBD bound to ACE2. ACE2 is shown in lime green. The SARS-CoV-2 RBD core is shown in purple and RBM in tint colour. The N-terminal helix of ACE2 responsible for binding is labelled .

It has been observed that COVID-19 pandemic intensity is different among regions. A country or region suffering the most may have been primed by exposure to one or more coronaviruses and encountered the effects of antibody-dependent enhancement (ADE) due to antigenic epitope heterogeneity (Tetro, 2020) . ADE is a phenomenon in which pre-existing non-or poorly neutralizing antibodies enhance the viral entry and replication in the host cell. ADE is more common in flaviviruses, especially in the dengue virus, which has four serotypes. It has been shown that when patients are infected with dengue virus for first time, specific neutralizing antibodies are produced. However, if they are later infected with a different serotype of dengue virus, the pre-existing antibodies from the previous infection do not have enough potency to neutralize the new virus, even though they can bind with the virus. These partially neutralizing antibodies help the virus to enter cells via an Fc-receptor (FcR)-mediated mechanism in addition to their natural entry route ( Figure 2A ). The antibody-bound viruses bind via the antibody Fcdomain to FcR expressed on the surface of several immune cells, leading to enhancement of the J o u r n a l P r e -p r o o f virus entry and replication (Katzelnick et al., 2017; Khandia et al., 2018) . ADE has also been reported in other viruses like HIV, Ebola, HCV, and Zika ( (Gorlani and Forthal, 2013; Meyer et al., 2008; Takada et al., 2001; Willey et al., 2011) . Vaccine-induced enhancement was first reported during the vaccine trial of RSV in 1969. In this trial, the administration of the formalininactivated vaccine RSV (FI-RSV) to naïve infants resulted in a much higher incidence rate of severe illness. It led to increased hospitalization in 80% among vaccinated infants, compared to only 5% of the non-immunized infants (Kim et al., 1969) . Unfortunately, two vaccinated infants also died because of enhanced RSV infections (Kim et al., 1969) .

ADE has also been reported in SARS-CoV and MERS-CoV. It has been shown that antispike sera, which can neutralize SARS-CoV pseudo viral particles, can initiate virus entry in cells that do not express the ACE2 receptor for SARS-CoV. ADE is based on the expression of FcR on cells (Jaume et al., 2011; Wang et al., 2014) . Another report suggests that ADE occurs through FcR in macrophages, but there are no changes in gene profiling, and virus replication has been shown to be abortive (Yip et al., 2016) . A recent study has shown that MERS-CoV RBD-specific MAb and the SARS-CoV RBD-specific MAb can mediate the entry of their respective coronaviruses into FcR-expressing human cells. This study also suggests that a fully neutralizing antibody can also mediate ADE by functionally mimicking viral receptors from host cells (Wan et al., 2019) . It has also been shown that passive transfer of anti-S IgG or serum from previously infected animals caused more severe lung injury in animal models .

There are huge theoretical concerns of vaccine-induced ADE which can occur in several scenarios. It is possible that vaccine-induced antibodies against SARS-CoV-2 may bind to the virus without neutralizing it. Currently mutations on the viral Spike protein have been found in circulating clinical SARS-CoV-2 strains (Korber et al., 2020; Lu et al., 2020) . If this happen, the J o u r n a l P r e -p r o o f non-neutralizing antibodies could produce ADE effect and enhance the viral entry into cells (Garber, 2020; Iwasaki and Yang, 2020; Tetro, 2020; Ulrich et al., 2020) . In addition, significant sequence variations between the spike proteins of SARS-CoV and SARS-CoV-2 may cause ADE (Tetro, 2020) . Moreover, it is also possible that a future SARS-related (SARSr)-CoV causes ADE in patients vaccinated with SARS-CoV-2, if the future SARSr-CoV shows significant sequence variations from SARS-CoV-2. Furthermore, insufficient concentration of neutralizing Ab may also cause ADE (Renner et al., 2018; Wan et al., 2019) . Given the fact that neutralizing antibodies declined rapidly in some of COVID-19 patients Seow et al., 2020) , this latter scenario is more troublesome. Nevertheless, based on the knowledge from research on SARS-CoV, several vaccine trials are ongoing for SARS-CoV-2.

Soon after the discovery of the nanobody in the camelid family by C. Hamers-Casterman and colleagues in 1993 (Hamers-Casterman et al., 1993) , it became a potent tool as a neutralizing antibody. Several nanobodies have been screened and validated for binding against different targets ranging from human melanoma cells to viruses. A nanobody against human melanoma cells targeting endothelin receptor type B has been recently identified, which will be helpful in the future to treat human melanoma . Besides, several nanobodies have been identified to block the ligand-receptor binding for primary immune cells. For example, nanobodies inhibiting PD1-PDL1 interaction, LIN28:let-7 interaction, and T cell marker CD3 are all promising candidates for targeting and activating cytotoxic T lymphocytes (CTLs) to induce anti-tumor responses. GRP78, CD38, and GPC3 expression on cancer cells have also been targeted for nanobody expression and purification, which provide useful cancer cell markers and J o u r n a l P r e -p r o o f potential therapeutic markers (Aghamollaei et al., 2020, p. 78; Hambach et al., 2020; Li et al., 2020; Moradi-Kalbolandi et al., 2020; .

One drawback of use of nanobody is the absence of antibody-dependent cellular cytotoxicity (ADCC). Since nanobody lacks the Fc portion so it is unable to bind to immune cells to provide ADCC effect. It has been shown that non protective antibodies help in protection from HIV (Forthal et al., 2001; Haynes et al., 2012) , herpes simplex virus (Kohl et al., 2000; Loo, 1982, 1982) , Ebola virus Saphire et al., 2018) , and influenza virus (Greenberg et al., 1977; Jegaskanda et al., 2014) , and SARS-CoV (Yasui et al., 2014) by mechanism of ADCC. Therefore, the use of nanobody has both benefits and drawbacks.

Nanobody provides protection against ADE, however, it lacks ADCC. It is very important to balance the adverse effect of ADE and beneficial effect of ADCC. To this end, it is important to note that nanobody can be easily engineered to add different effector function such as Fc regions, toxins, liposomes, and other ligand binding scaffolds (Harmsen et al., 2005; Laursen et al., 2018; Schriewer et al., 2020) . Recently, the European Medicines Agency (EMA) and the US Food and Drug Administration (FDA) have approved a bivalent nanobody, caplacizumab, for treatment of patients with thrombotic thrombocytopenic purpura (Hanlon and Metjian, 2020; Scully et al., 2019) .

Several nanobodies have been reported to act as potential therapeutic agents against different viruses. Nanobodies against viruses work on the principle of inhibiting the ligandreceptor interaction (Figure 2 A&B) . A nanobody against HCV has been reported which blocks the E2-CD81 interaction and stops the virus-cell to cell transmission (Tarr et al., 2013) . A replication-inhibiting nanobody against porcine reproductive and respiratory syndrome virus (PRRSV), which is a significant threat to the swine industry, has been identified and provides a J o u r n a l P r e -p r o o f novel antiviral drug for inhibition of PRRSV replication and controlling PRRSV disease (Duan et al., 2020; Wang et al., 2019) . Another intracellular antibody directed towards human papillomavirus (HPV) oncoprotein E7 has shown great potential for therapy of HPV16associated disease . Nanobodies have also exhibited good antiviral effects against bovine viral diarrhea virus .

Only limited studies have been performed on nanobodies against coronaviruses. A few groups investigated nanobody activity against the MERS-CoV S protein and successfully found nanobodies that could neutralize MERS-CoV in pseudo-viral particles and in a mouse model (Raj et al., 2018; Zhao et al., 2018) . Recently, nanobodies against SARS-CoV have also been identified which have shown cross-neutralization activity, and therefore have excellent therapeutic potential against the SARS-CoV-2 virus (Wrapp et al., 2020a) . Several other nanobodies have been identified recently that act against the SARS-CoV-2 receptor-binding domain (Chi et al., 2020; Walter et al., 2020; . Fc portion and is unable to bind to the Fcγ receptor, which protects the cell from antibodydependent enhancement (created with BioRender.com).

Protein-based subunit vaccines are probably one of the safest formats of vaccine, but immune responses generated with this kind of vaccine are heavily dependent on the adjuvant used. The S protein in different form including full-length S Protein, S1 RBD, RBD-Fc, and N-terminal, have shown nAb responses and protection in multiple animal models and nonhuman primates (Deng et al., 2018; Lan et al., 2015; Tse et al., 2020; Wang et al., 2017; Zhang et al., 2016) .

DNA vaccines are composed of plasmid DNA molecules encoding one or more immunogens. A DNA vaccine is better than an mRNA vaccine in terms of the formulation required for its stability and ease of delivery. However, there is a risk that integration of the vaccine into the host genome may create mutations (Ledwith et al., 2000; Liu, 2019) . Passive transfer of sera from mice immunized with DNA encoding the MERS-CoV S domain has been shown to protect naïve mice from MERS-CoV infection (Chi et al., 2017) . Other research showed that the DNA encoding the S1 domain is superior to that with full length S protein in eliciting antibody and Th1/Th2 responses. Both DNAs encoding the S1 and S proteins were shown to induce crossneutralizing Abs against multiple strains of MERS-CoV from human and camel origins (Al-amri et al., 2017) . Another study showed that sera from mice immunized with S protein-encoding J o u r n a l P r e -p r o o f DNA detects SARS-CoV S protein (Zhao et al., 2004) . Mice immunized with S protein-encoding DNA and booted with CD4+ and CD8+ T cell-specific peptides improves the expression of several cytokines (Huang et al., 2007) . Another report shows that DNA encoding the S protein from SARS-CoV elicits neutralizing antibodies, as measured by a Pseudotyped lentiviral vector reporter neutralization assay and S protein-specific CD4+ and CD8+ T-cell responses in all immunized volunteer (Martin et al., 2008) . Recently, Yu and colleagues reported that DNA vaccine encoding the SARS-CoV-2 S protein can protect rhesus macaques after challenge with SARS-CoV-2 (J. . Currently, two SARS-CoV-2 DNA vaccines are under development. Inovio Pharmaceuticals developed a DNA vaccine NCT043364, which is undergoing Phase 1 clinical trial. Several other companies are involved in the development of DNA vaccines, which is mentioned S protein-based DNA vaccine (Table 1) . 

A live attenuated Modified Vaccinia Ankara (MVA) vector encoding a full-length S glycoprotein has been shown to generate a potent neutralizing antibody in mice, rabbit, and monkey . Other studies show that immunization of mice with recombinant adenovirus containing the S protein induces both neutralizing antibodies in serum as well as CD8+ T cells in lungs (Du et al., 2006, p.; Kobinger et al., 2007; Liu et al., 2005; Shim et al., 2012) . Currently, different companies are involved in making replicating and non-replicating viral vector-based vaccines (Tables 2 and 3 , respectively). The University of Oxford's non-replicating adenovirus-based ChAdOx1 nCoV-19 vaccine has shown protection in rhesus macaques after challenge with SARS-CoV-2(van Doremalen et al., 2020).

Subunit vaccines use one or more antigens suitable for eliciting a robust immune response. In theory, the subunit vaccine is a very easy and safe vaccine, but in practice, it requires a suitable adjuvant to stimulate the host immune response. Several previous attempts were partially successful with SARS-CoV. Immunization of animals with the S1 RBD domain fused with the IgG1 FC portion (RBD-FC) induced highly potent antibodies which could bind with the RBD domain of the S1 domain, completely neutralize SARS-CoV, and inhibit SARS-CoV entry into Vero E6 cells (Du et al., 2009b He et al., 2004) . A similar approach is being used to develop a vaccine against the SARS-CoV-2 virus. Several companies, including the University of Queensland, are developing subunit vaccines based on the "molecular clamp" technology (Takashima et al., 2011) . Trimer-tag technology is being used by Clover Biopharmaceuticals, Inc. to develop a vaccine against SARS-CoV-2 using mammalian cell-expressed Trimeric S Table 4 .

mRNA has been used as a template for endogenous expression of proteins selected as a vaccine

candidate. An mRNA vaccine is a promising alternative because of its high potency, short production cycle, and low manufacturing cost. (Pardi et al., 2018; Yun et al., 2020) . Currently, there is no mRNA vaccine in the market, so it will be challenging to pass the quality control and safety evaluation. Currently, mRNA-1273, a potential vaccine against SARS-CoV-2 based on encoding for a prefusion stabilized form of the S protein, has been selected for evaluation by Moderna in collaboration with investigators at the NIAID Vaccine Research Center (VRC). This vaccine is currently the focus of a Phase 1 clinical trial (NCT04283461). Several other companies are also developing mRNA vaccines against SARS-CoV-2 (Table 5) .

Two S-protein-based methods that show promise as therapeutics for SARS-CoV-2 include those facilitating peptide interference with RBD-ACE2 interaction, as well as those using mAbs that target the S-protein. A previous study has shown that hexapeptide 438 YKYRYL 443 from the S J o u r n a l P r e -p r o o f protein of SARS-CoV virus binds to ACE2 with a binding affinity of KD = 46 μM and blocks the entry of SARS-CoV into Vero E6 cells (Struck et al., 2012) . A peptide from the RBD domain of the S protein (aa 471-503) can inhibit the binding of ACE2 to SARS-CoV RBD and block SARS-CoV entry into Vero cells with an EC50 of 41.6 μM (Hu et al., 2005) . Similarly, a combination of two peptides from ACE2 motif aa 22-44 and 351-357 linked together by glycine blocks entry of SARS pseudoparticles in HeLa cells expressing ACE2 protein with EC50 of 100 μM (Han et al., 2006) . Recently it has been shown that a 23-mer spike binding peptide 1 (IEEQAKTFLDKFNHEAEDLFYQS) derived from human ACE2 a1 helix binds SARS-CoV-2-RBD with low nanomolar affinity (dissociation constant, KD = 47 nM), potentially inhibiting the entry of the virus into human cells (G. . Another study showed that the lapidated form of peptide EK1, EK1C inhibits SARS-CoV-2 mediated cell-cell fusion at the concentration of 2.5 μM and with an IC50 of 48.1 nM. This study also suggests that lipidation, as well as linker length, plays an essential role in the overall activity of lipopeptides. (S. . This would be a potential candidate for therapeutic development. However, its efficacy against SARS-CoV-2 still needs to be validated using an in vivo model. Several monoclonal antibodies targeting the S protein against SARS-CoV have been identified that inhibit the virus entry to cells (Sui et al., 2004; ter Meulen et al., 2006 ter Meulen et al., , 2004 Traggiai et al., 2004; Zhu et al., 2007) . Although RBD of the S protein is the prime target for neutralizing antibodies, antibodies can recognize different epitopes on RBD and work synergistically. The SARS-CoV neutralizing antibodies CR3014 and CR3022 bind noncompetitively to the SARS-CoV RBD and synergistically neutralize the virus (ter Meulen et al., 2006) . A recent report revealed that although a SARS-CoV-neutralizing antibody m396 showed promising binding with J o u r n a l P r e -p r o o f SARS-CoV-2 RBD in computational modeling, it only showed slight binding at the highest measured concentration (2.0 μM) in an experimental condition. Another study found that plasma samples from SARS-CoV-convalescent patients can neutralize SARS-CoV, but cannot crossneutralize SARS-CoV-2, even though they can bind SARS-CoV-2 . These results suggest that monoclonal antibodies that bind with SARS-CoV S protein are unable to bind SARS-CoV-2. These results suggest an urgent need to develop novel monoclonal antibodies that could bind specifically to SARS-CoV-2 .

Another area of research which can provide immediate control of SARS-CoV-2 spreads is the small molecule inhibitors. Several previous reports have suggested that small molecule compound can successfully inhibit the interaction between SARS-CoV spike protein and ACE2, leading to block the virus entry into the cells (Adedeji et al., 2013; Huentelman Matthew J. et al., 2004; Kao et al., 2004) . Similar study in SARS-CoV-2 suggest that small molecule can inhibit the interaction between SARS-CoV-2 and ACE2. Hanson et. al., have performed a drug repurposing screen against 3,384 small molecule drugs using a proximity -based assay which measure the binding of SARS-CoV2 spike protein Domain (RBD) and ACE2, and found 25 high quality small molecule hits that can be evaluated for its efficacy in future (Hanson et al., 2020) . Even though druggable pockets are absent in spike protein and ACE2 in their unbound states, bound states have well defined pockets for drug development.

Using computer modeling, Patil et al has shown that several antiviral compound against HCV and HIV viruses e.g. Atazanavir, Grazoprevir, Saquinavir, Simeprevir, Telaprevir and Tipranavir could be potential candidate inhibitors for immediate future investigation (Patil et al., 2020) .

The emergence of the COVID-19 pandemic has underscored the necessity to find therapeutics and/or vaccines to control the spread of infection and save infected people. From recent and previous studies of SARS-CoV, MERS-CoV, and SARS-CoV-2, it is well known that the S protein plays a vital role in virus-host interaction and its entry into human cells. Still, we need to know more about the fundamental nature of SARS-CoV-2, for example, mechanisms of pathogenesis, cellular and humoral immune response in the host after virus infection, etc., to make a successful therapeutics and/or vaccine.

In this review, we summarised different approaches using the S protein to generate a vaccine, therapeutics, or neutralizing antibodies targeting SARS-CoV-2. Several neutralizing antibodies have been detected that act against SARS-CoV or MERS-CoV, but with limited success. Many of the neutralizing antibodies or vaccines identified cause ADE or vaccine-enhanced disease, respectively. There is a rising concern about ADE effect by sub-optimal antibody generated by vaccine under development against SARS-CoV-2. Because of these risks, it is crucial to perform large-scale clinical trials to assess vaccine or therapeutic efficacy and safety before approving any for widespread use. It is also essential to find a neutralizing antibody which can neutralize different strain of viruses and yet not cause antibody-induced enhancement. Use of nanobodies is one of the options that can successfully avoid the ADE effect. Since the virus is still spreading globally, a vaccine is the preferred means to control COVID-19. Development, testing, and clinical trials are ongoing with a focus on identifying a potential drug/vaccine to prevent or treat SARS-CoV-2-associated disease.

Recent studies have shown that SARS-CoV-2 is actively evolving. Recently, it was found that a clinical strain of SARS-CoV-2 containing a D614G mutation within the viral spike protein is now dominant in many countries (Korber et al., 2020) . It has been reported in several studies that this mutation is not causing patient sicker but has higher rate of infectivity than the wild-type virus (Daniloski et al., 2020; Eaaswarkhanth et al., 2020; Ogawa et al., 2020; ) . D614G did not alter the virus's response to antibodies from patients infected with the wild-type virus, which suggests that vaccines currently under development based on the original viral spike protein will be still effective against the new strain (Grubaugh et al., 2020; . However, in order to fully establish the safety, cross-challenging studies of the new strain in vaccinated animals should be performed to evaluate the biosafety of vaccines. and-fosun-pharma-bnt162/. Accessed on July 29, 2020.," n.d.)

Imperial College London

Self-amplifying RNA vaccine will deliver genetic instructions to muscle cells to make the 'S' protein on the surface of the coronavirus. This should provoke an immune response and create immunity to COVID-19

Phase 1 ISRCTN17072692 ("Imperial College London.

https://www.clinicaltrialsarena.com/news/imperial-college-covidvaccine/. Accessed on July 29, 2020.," n.d.)

Curevac mRNA NCT04449276

("Curevac. https://www.curevac.com/news/curevac-receivesregulatory-approval-from-german-and-belgian-authorities-to-initiatephase-1-clinical-trial-of-its-sars-cov-2-vaccine-candidate. Accessed on July 29, 2020.," n.d.)

Saiba GmbH 

Novel Inhibitors of Severe Acute Respiratory Syndrome Coronavirus Entry That Act by Three Distinct Mechanisms

BARBARIAN NORDIC enters agreement with ADAPVAC to advance COVID-19 vaccine program

Isolation and characterization of a novel nanobody for detection of GRP78 expressing cancer cells

AJ Vaccines to develop vaccine for COVID-19

Immunogenicity of Candidate MERS-CoV DNA Vaccines Based on the Spike Protein

The history and epidemiology of Middle East respiratory syndrome corona virus

SARS-CoV-2 Vaccines: Status Report

An updated guide to the coronavirus drugs and vaccines in development

AnhuiZhifei/Adjuvanted-recombinant-protein-Anhui-Zhifei-Longcom-Biopharma-Institute-of-Microbiology-Chinese-Acad. Accessed on

Incubation period of 2019 novel coronavirus (2019-nCoV) infections among travellers from Wuhan, China

BEJING Institute of Biological Products/Sinopharma

Begins Developing COVID-19 Vaccine

Six Indian companies working on coronavirus vaccine

BioNet in Thailand is developing a COVID-19 GENE-based vaccine (COVIGEN) encoding the S (Spike) protein of SARS-CoV-2

The coronavirus spike protein is a class I virus fusion protein: structural and functional characterization of the fusion core complex

Viral vectors: from virology to transgene expression

Remdesivir for severe acute respiratory syndrome coronavirus 2 causing COVID-19: An evaluation of the evidence

CEPI. CEPI collaborates with the Institut Pasteur in a consortium to develop COVID-19 vaccine

Yeast-expressed recombinant protein of the receptor-binding domain in SARS-CoV spike protein with deglycosylated forms as a SARS vaccine candidate

Recombinant modified vaccinia virus Ankara expressing the spike glycoprotein of severe acute respiratory syndrome coronavirus induces protective neutralizing antibodies primarily targeting the receptor binding region

DNA vaccine encoding Middle East respiratory syndrome coronavirus S1 protein induces protective immune responses in mice

Humanized Single Domain Antibodies Neutralize SARS-CoV-2 by Targeting Spike Receptor Binding Domain (preprint)

Cobra Biologics. Cobra Biologics and the Karolinska Institute collaborate to develop COVID-19 vaccine

Purified coronavirus spike protein nanoparticles induce coronavirus neutralizing antibodies in mice

MERS-CoV spike nanoparticles protect mice J o u r n a l P r e -p r o o f from MERS-CoV infection

COVID-19 Vaccine Candidate Shows Promise

COVID-19 vaccine: Dendritic cell-based vaccine

Origin and evolution of pathogenic coronaviruses

The D614G mutation in SARS-CoV-2 Spike increases transduction of multiple human cell types

Roles of Host Gene and Non-Coding RNA Expression in Virus Infection, Current Topics in Microbiology and Immunology

Aminopeptidase N is a major receptor for the entero-pathogenic coronavirus TGEV

Enhanced protection in mice induced by immunization with inactivated whole viruses compare to spike protein of middle east respiratory syndrome coronavirus

Recombinant adeno-associated virus expressing the receptor-binding domain of severe acute respiratory syndrome coronavirus S protein elicits neutralizing antibodies: Implication for developing SARS vaccines

The spike protein of SARS-CoV -a target for vaccine and therapeutic development

A truncated receptor-binding domain of MERS-CoV spike protein potently inhibits MERS-CoV infection and induces strong neutralizing antibody responses: implication for developing therapeutics and vaccines

Recombinant receptor-binding domain of SARS-CoV spike protein expressed in mammalian, insect and E. coli cells elicits potent neutralizing antibody and protective immunity

Receptor-binding domain of SARS-CoV spike protein induces long-term protective immunity in an animal model

A novel intracellularly expressed NS5B-specific nanobody suppresses bovine viral diarrhea virus replication

Cloning of the mouse hepatitis virus (MHV) receptor: expression in human and hamster cell lines confers susceptibility to MHV

Could the D614G substitution in the SARS-CoV-2 spike (S) protein be associated with higher COVID-19 mortality?

EpiVax Accelerates COVID-19 Vaccine Development with UGA's Center for Vaccines and Immunology

The US Army's Virus Research Lab Gears Up to Fight Covid-19

ExpreS2ion Announces Bavarian Nordic Enters Agreement with AdaptVac to Advance the COVID-19 Vaccine

COVID-19-Vaccine-Development-Program

Evidence that TMPRSS2 activates the severe acute respiratory syndrome coronavirus spike protein for membrane fusion and reduces viral control by the humoral immune response

Major receptor-binding and neutralization determinants are located within the same domain of the transmissible gastroenteritis virus (coronavirus) spike protein

Remdesivir is a direct-acting antiviral that inhibits RNAdependent RNA polymerase from severe acute respiratory syndrome coronavirus 2 with high potency

Systems Biology

Antibody-dependent enhancement and the risk of HIV infection

Lymphocyte cytotoxicity to influenza virus-infected cells. II. Requirement for antibody and non-T lymphocytes

Greffex completes COVID-19 vaccine, prepares for FDA animal testing

Making Sense of Mutation: What D614G Means for the COVID-19 Pandemic Remains Unclear

Joins Xiamen Innovax Biotech to Support COVID-19 Vaccine Development & Expands Activity to Fight War against Pandemic

A Role for Fc Function in Therapeutic Monoclonal Antibody-Mediated Protection against Ebola Virus

2020. Targeting CD38-Expressing Multiple Myeloma and Burkitt Lymphoma Cells In Vitro with Nanobody-Based Chimeric Antigen Receptors (Nb-CARs). Cells 9

Naturally occurring antibodies devoid of light chains

Identification of critical determinants on ACE2 for SARS-CoV entry and development of a potent entry inhibitor

Caplacizumab in adult patients with acquired thrombotic thrombocytopenic purpura

Biotech and academia collaborate on intranasal COVID-19 vaccine development

Targeting ACE2-RBD interaction as a platform for COVID19 therapeutics: Development and drug repurposing screen of an AlphaLISA proximity assay

Prolonged in vivo residence times of llama single-domain antibody fragments in pigs by binding to porcine immunoglobulins

Immune-Correlates Analysis of an HIV-1 Vaccine Efficacy Trial

Receptorbinding domain of SARS-CoV spike protein induces highly potent neutralizing antibodies: implication for developing subunit vaccine

Heat Biologics Announces Research Collaboration with University of Miami to Develop Vaccine Designed to Protect Against

SARS-CoV-2 Cell Entry Depends on ACE2 and TMPRSS2 and Is Blocked by a Clinically Proven Protease Inhibitor

S protein of severe acute respiratory syndrome-associated coronavirus mediates entry into hepatoma cell lines and is targeted by neutralizing antibodies in infected patients

Human coronavirus NL63 employs the severe acute respiratory syndrome coronavirus receptor for cellular entry

Screening and identification of linear B-cell epitopes and entry-blocking peptide of severe acute respiratory syndrome (SARS)-associated coronavirus using synthetic overlapping peptide library

Priming with SARS CoV S DNA and boosting with SARS CoV S epitopes specific for CD4+ and CD8+ T cells promote cellular immune responses

Structure-Based Discovery of a Novel Angiotensin-Converting Enzyme 2 Inhibitor

Coronavirus Spike Protein and Tropism Changes

Biosciences Announce Collaboration on VSV-vector Based Epidemic Preparedness Vaccines

Improvement of Pharmacokinetic Profile of TRAIL via Trimer-Tag Enhances its Antitumor Activity in vivo

IVI-Partner-with-Seoul-National-University-Hospital-to-Start-Phase-12-Clinical-Trial-of-INOVIOs-COVID-19-DNA-Vaccine-INO-4800-in-South-Korea/default

The potential danger of suboptimal antibody responses in COVID-19

An mRNA Vaccine against SARS-CoV-2 -Preliminary Report

Anti-severe acute respiratory syndrome coronavirus spike antibodies trigger infection of human immune cells via a pH-and cysteine protease-independent FcγR pathway

Influenza-specific antibodydependent cellular cytotoxicity: toward a universal influenza vaccine

A high affinity nanobody against endothelin receptor type B: a new approach to the treatment of melanoma

An emerging coronavirus causing pneumonia outbreak in Wuhan, China: calling for developing therapeutic and prophylactic strategies

Neutralizing Antibodies against SARS-CoV-2 and Other Human Coronaviruses

Announces a Lead Vaccine Candidate for COVID-19; Landmark New Partnership with U.S. Department of Health & Human Services; and Commitment to Supply One Billion Vaccines Worldwide for Emergency Pandemic Use

Identification of Novel Small-Molecule Inhibitors of Severe Acute Respiratory Syndrome-Associated Coronavirus by Chemical Genetics

Antibody-dependent enhancement of severe dengue disease in humans

Modulation of Dengue/Zika Virus Pathogenicity by Antibody-Dependent Enhancement and Strategies to Protect Against Enhancement in Zika Virus Infection

Microneedle array delivered recombinant coronavirus vaccines: Immunogenicity and rapid translational development. EBioMedicine 102743

Respiratory syncytial virus disease in infants despite prior administration of antigenic inactivated vaccine

Adenovirus-based vaccine prevents pneumonia in ferrets challenged with the SARS coronavirus and stimulates robust immune responses in macaques

Limited Antibody-Dependent Cellular Cytotoxicity Antibody Response Induced by a Herpes Simplex Virus Type 2 Subunit Vaccine

Protection of neonatal mice against herpes simplex virus infection: probable in vivo antibody-dependent cellular cytotoxicity

Point mutations in the S protein connect the sialic acid binding activity with the enteropathogenicity of transmissible gastroenteritis coronavirus

Structure of the SARS-CoV-2 spike receptorbinding domain bound to the ACE2 receptor

Recombinant Receptor Binding Domain Protein Induces Partial Protective Immunity in Rhesus Macaques Against Middle East Respiratory Syndrome Coronavirus Challenge

The Incubation Period of Coronavirus Disease 2019 (COVID-19) From Publicly Reported Confirmed Cases: Estimation and Application

Universal protection against influenza infection by a multidomain antibody to influenza hemagglutinin

Plasmid DNA vaccines: assay for integration into host genomic DNA

A major outbreak of severe acute respiratory syndrome in Hong Kong

Functional assessment of cell entry and receptor usage for SARS-CoV-2 and other lineage B betacoronaviruses

Structure, Function, and Evolution of Coronavirus Spike Proteins

Receptor Recognition Mechanisms of Coronaviruses: a Decade of Structural Studies

Nanobody against PDL1

Nanobody against the E7 oncoprotein of human papillomavirus 16

Selection and characterization of specific nanobody against bovine virus diarrhea virus (BVDV) E2 protein

Angiotensin-converting enzyme 2 is a functional J o u r n a l P r e -p r o o f receptor for the SARS coronavirus

Identification of residues in the receptor-binding domain (RBD) of the spike protein of human coronavirus NL63 that are critical for the RBD-ACE2 receptor interaction

Incubation Period and Other Epidemiological Characteristics of 2019 Novel Coronavirus Infections with Right Truncation: A Statistical Analysis of Publicly Available Case Data

Anti-spike IgG causes severe acute lung injury by skewing macrophage responses during acute SARS-CoV infection

A Comparison of Plasmid DNA and mRNA as Vaccine Technologies

Adenoviral expression of a truncated S1 subunit of SARS-CoV spike protein results in specific humoral immune responses against SARS-CoV in rats

Clinical and immunological assessment of asymptomatic SARS-CoV-2 infections

Genomic characterisation and epidemiology of 2019 novel coronavirus: implications for virus origins and receptor binding

Isabel Sola y Sonia Zúñiga. NOVEL HUMAN PATHOGENIC CORONAVIRUS: SARS-CoV-2

Cross-reactive antibody response between SARS-CoV-2 and SARS-CoV

A SARS DNA vaccine induces neutralizing antibody and cellular immune responses in healthy adults in a Phase I clinical trial

Compounds with Therapeutic Potential against Novel Respiratory

The Molecular Biology of Coronaviruses

Efficient Activation of the Severe Acute Respiratory Syndrome Coronavirus Spike Protein by the Transmembrane Protease TMPRSS2

The insert sequence in SARS-CoV-2 enhances spike protein cleavage by TMPRSS

Antibody-Dependent Enhancement of Hepatitis C Virus Infection

Evaluation the potential of recombinant anti-CD3 nanobody on immunomodulatory function

The receptor binding domain of the new Middle East J o u r n a l P r e -p r o o f respiratory syndrome coronavirus maps to a 231-residue region in the spike protein that efficiently elicits neutralizing antibodies

Supramolecular Architecture of Severe Acute Respiratory Syndrome Coronavirus Revealed by Electron Cryomicroscopy

The D614G mutation in the SARS-CoV2 Spike protein increases infectivity in an ACE2 receptor dependent manner

OncoGen researchers propose personalized vaccinomics strategy for the novel China coronavirus

mRNA vaccines -a new era in vaccinology

Drug Repurposing for Covid-19: Discovery of Potential Small-Molecule Inhibitors of Spike Protein-ACE2 Receptor Interaction Through Virtual Screening and Consensus Scoring

Coronavirus Infections-More Than Just the Common Cold

Pharmajet partner with ITI and EpiVax to develop and deliver COVID-10 Vaccine

Dipeptidyl peptidase 4 is a functional receptor for the emerging J o u r n a l P r e -p r o o f human coronavirus-EMC

Chimeric camel/human heavychain antibodies protect against MERS-CoV infection

New Vaccine Technologies to Combat Outbreak Situations

Leukocare and Univercells announce fast-track development of a COVID-19 vaccine

Characterization of a potent and highly unusual minimally-enhancing antibody directed against dengue virus

Saiba proprietary technology has enabled scientists to generate a vaccine candidate against COVID-19 with preclinical proof-of-concept

Saint-Petersburg scientific research institute of vaccines and serums

The Novel Coronavirus, 2019-nCoV, is Highly Contagious and More Infectious Than Initially Estimated (preprint)

Sanofi and GSK to join forces in unprecedented vaccine collaboration to fight COVID-19

Systematic analysis of monoclonal antibodies against Ebola virus GP defines features that contribute to protection

SARS-CoV-2: DZIF scientists and the development of vaccines

Nanobody-based CD38-specific heavy chain antibodies induce killing of multiple myeloma and other hematological malignancies

The S protein of bovine coronavirus is a hemagglutinin recognizing 9-O-acetylated sialic acid as a receptor determinant

Caplacizumab Treatment for Acquired Thrombotic Thrombocytopenic Purpura

Longitudinal evaluation and decline of antibody

Cell entry mechanisms of SARS-CoV-2

Sublingual immunization with recombinant adenovirus encoding SARS-CoV spike protein induces systemic and mucosal immunity without redirection of the virus to the brain

Shionogi Accelerates Development of Potential COVID-19 Treatments and Vaccine

A transmembrane serine protease is linked to the severe acute respiratory syndrome coronavirus receptor and activates virus entry

The M, E, and N Structural Proteins of the Severe Acute Respiratory Syndrome Coronavirus Are Required for Efficient Assembly, Trafficking, and Release of Virus-Like Particles

A hexapeptide of the receptor-binding domain of SARS corona virus spike protein blocks viral entry into host cells via the human receptor ACE2

Epidemiology, Genetic Recombination, and Pathogenesis of Coronaviruses

Potent neutralization of severe acute respiratory syndrome (SARS) coronavirus by a human mAb to S1 protein that blocks receptor association

Evaluating the Safety, Tolerability, and Immunogenicity of bacTRL-Spike Vaccine for Prevention of COVID-19

Characterization of the receptor-binding domain (RBD) of 2019 novel J o u r n a l P r e -p r o o f coronavirus: implication for development of RBD protein as a viral attachment inhibitor and vaccine

A recombinant receptor-binding domain of MERS-CoV in trimeric form protects human dipeptidyl peptidase 4 (hDPP4) transgenic mice from MERS-CoV infection

Infectivity-Enhancing Antibodies to Ebola Virus Glycoprotein

Artificial Molecular Clamp: A Novel Device for Synthetic Polymerases

Rome, announces that it is ready to test its Covid-19 vaccine on pre-clinical models

An alpaca nanobody inhibits hepatitis C virus entry and cell-to-cell transmission

Human monoclonal antibody as prophylaxis for SARS coronavirus infection in ferrets

Human monoclonal antibody combination against SARS coronavirus: synergy and coverage of escape mutants

Is COVID-19 receiving ADE from other coronaviruses? Microbes and Infection

Potent binding of 2019 novel coronavirus spike protein by a SARS coronavirus-specific human monoclonal antibody

TNX-1800 Horsepox vector for S protein

An efficient method to make human monoclonal antibodies from memory B cells: potent neutralization of SARS coronavirus

A Cluster of Cases of Severe Acute Respiratory Syndrome in Hong Kong

The Current and Future State of Vaccines, Antivirals and Gene Therapies Against Emerging Coronaviruses

Dengue Fever, COVID-19 (SARS-CoV-2), and Antibody-Dependent Enhancement (ADE): A Perspective

CEPI partners with University of Hong Kong to develop COVID-19 vaccine

University of Tokoyo and Daiichi Sankyo. Our Company's Efforts to Limit the Spread of the Virus that Causes COVID-19 Accessed

USask. USask VIDO-InterVac awarded $23M for COVID-19 vaccine research

Vaxart Announces Additional Positive Pre-Clinical Data for its Oral COVID-19 Vaccine Program

Vaxil commences preclinical COVID-19 vaccine trial and files an additional COVD-19 patent

Structure, Function, and Antigenicity of the SARS-CoV-2 Spike Glycoprotein

Synthetic nanobodies targeting the SARS-CoV-2 receptor-binding domain

Molecular Mechanism for Antibody

Dependent Enhancement of Coronavirus Entry

A novel coronavirus outbreak of global health concern

A Nanobody Targeting Viral Nonstructural Protein 9 Inhibits Porcine Reproductive and Respiratory Syndrome Virus Replication

Structural and Functional Basis of SARS-CoV-2 Entry by Using Human ACE2

Antibody-dependent SARS coronavirus infection is mediated by antibodies against spike proteins

Receptor-binding domain of MERS-CoV with optimal immunogen dosage and immunization interval protects human transgenic mice from MERS-CoV infection

Draft landscape of COVID-19 candidate vaccines

Middle East respiratory syndrome coronavirus (MERS-CoV)

WHO. Novel Coronavirus(2019-nCoV) Situation Report -22

Extensive complement-dependent enhancement of HIV-1 by autologous non-neutralising antibodies at early stages of infection

Receptor for mouse hepatitis virus is a member of the carcinoembryonic antigen family of glycoproteins

Structural Basis for Potent Neutralization of Betacoronaviruses by Single-domain Camelid Antibodies (preprint)

Cryo-EM structure of the 2019-nCoV spike in the prefusion conformation

A new coronavirus associated with human respiratory disease in China

Identification of Human Single-Domain Antibodies against SARS-CoV-2

Preparation and Characterization of Anti-GPC3 Nanobody Against Hepatocellular Carcinoma

Inhibition of SARS-CoV-2 (previously 2019-nCoV) infection by a highly potent pancoronavirus fusion inhibitor targeting its spike protein that harbors a high capacity to mediate membrane fusion

Phagocytic cells contribute to the antibody-mediated elimination of pulmonary-infected SARS coronavirus

Antibody-dependent SARS coronavirus infection and its role in the pathogenesis of SARS

A nanobody targeting the LIN28:let-7 interaction fragment of TUT4 blocks uridylation of let-7

Progress and challenge of vaccine development against 2019 novel coronavirus (2019-nCoV)

The first-inclass peptide binder to the SARS-CoV-2 spike protein

The D614G mutation in the SARS-CoV-2 spike protein reduces S1 shedding and increases infectivity

Identification of an ideal adjuvant for receptor-binding domainbased subunit vaccines against Middle East respiratory syndrome coronavirus

A Novel Nanobody Targeting Middle East Respiratory Syndrome Coronavirus (MERS-CoV) Receptor-Binding Domain Has Potent Cross

Neutralizing Activity and Protective Efficacy against MERS-CoV

DNA vaccine of SARS-Cov S gene induces antibody response in mice

Epidemiology and cause of severe acute respiratory syndrome (SARS) in Guangdong, People's Republic of China

A pneumonia outbreak associated with a new coronavirus of probable bat origin

Safety, tolerability, and immunogenicity of a recombinant adenovirus type-5 vectored COVID-19 vaccine: a dose-escalation, openlabel, non-randomised, first-in-human trial

Potent cross-reactive neutralization of SARS coronavirus isolates by human monoclonal antibodies

Zydus Cadila accelerates COVID-19 vaccine research

Zydus Cadila looks to expedite Covid-19 vaccine development

Anti-spike IgG causes severe acute lung injury by skewing macrophage responses during acute SARS-CoV infection

Unexpected Receptor Functional Mimicry Elucidates Activation of Coronavirus Fusion

Enhanced inflammation in New Zealand white rabbits when MERS-CoV reinfection occurs in the absence of neutralizing antibody

Zydus Cadila. Zydus Cadila looks to expedite Covid-19 vaccine development

CEPI. CEPI collaborates with the Institut Pasteur in a consortium to develop COVID-19 vaccine

Tonix Pharma/ Southern Research Horsepox vector expressing S protein Pre-Clinical

BiOCAD and IEM This viral vector vaccine based on attenuated influenza virus backbone (intranasal)

University of Hong Kong Influenza vector expressing RBD on its surface to induce immunogenicity against the SARS-CoV-2 virus; notably, can be administered as a nasal spray Pre-Clinical

Replication-competent VSV chimeric virus technology (VSVΔG) delivering the SARS-CoV-2 Spike (S) glycoprotein

University of Western Ontario VSV-S (Vesicular Stomatitis Virus-S) previously successfully used for the development of a vaccine for MERS Pre-Clinical

Wuhan Institue of Biological Products/Snopharm

BEJING Institute of Biological Products/Sinopharma

We thank Dr. McClive-Reed of Heath Research, Inc. for helpful suggestions. HL was partially supported by NIH grants AI131669, AI133219, AI140491, AI134568, AI140406, AI141178, and AI140726.J o u r n a l P r e -p r o o f

Phase 1 NCT04436471 NCT04437875("Gamaleya Research Institute. https://www.trialsitenews.com/gamaleyaresearch-institute-developed-covid-19-vaccine-clinical-trial-commencesacross-russia/. Accessed on JUly 29, 2020.," n.d.)GeoVax/BravoVax The aim of this vaccine is prevention/ control of SARS-CoV-2, using its GV-MVA-VLPTM vaccine platform . https://www.jnj.com/johnson-johnson-announces-a-lead-vaccinecandidate-for-covid-19-landmark-new-partnership-with-u-s-department-ofhealth-human-services-and-commitment-to-supply-one-billion-vaccinesworldwide-for-emergency-pandemic-use . Accessed approved-to-proceed. Accessed on July 29, 2020.," n.d.)